Chronic schizophrenia. Paranoid schizophrenia
Conditions
Interventions
Intervention 1: Interference Group: this group includes chronic schizophrenia patients that receive Rivastigmine capsules (1.5 mg) twice daily along with the previous antipsychotic medication for eigh
at the start point, after four weeks and at the end of eight weeks, using PANSS questionnaires and life quality. Intervention 2: Control group: this group includes chronic schizophrenia patients that
at the start point, after four weeks and at the end of eight weeks, using PANSS questionnaires and life quality.
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients with Chronic Schizophrenia Patients treated with Antipsychotics
Exclusion criteria
Exclusion criteria: Drug abuse IQ less than 70 ?Another psychiatric disorder Physical illness ECT in the last two weeks Sensitivity to Rivastigmine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of Rivastigmine. Timepoint: Efficacy of Rivastigmine in three stages: at the start point, after 4 weeks and at the end of study. Method of measurement: Positive, negative symptoms questionnaire in Chronic schizophrenia patients.;Efficacy of rivastigmine. Timepoint: Efficacy of Rivastigmine in three stages: at the start point, after 4 weeks and at the end of study. Method of measurement: Quality of Life Questionnaire in Chronic schizophrenic Patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effect. Timepoint: Two months after starting therapy. Method of measurement: Medical history and examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Jahangiri
Tabriz University of Medical Sciences
Outcome results
None listed